Biotech RadarJobs updated

COMPANY

Allay Therapeutics

HQ: Menlo Park, CA source · allaytx.com ↗ · West Coast

Clinical Phase 2

Allay Therapeutics is listed on ClinicalTrials.gov as the lead sponsor of 2 studies; the most recently updated is “Study Assessing Pain Relief After Replacement of the Knee” (Phase 2, completed), in Total Knee Arthroplasty (Postoperative Pain). Allay Therapeutics has received NIH funding, most recently in fiscal 2020 for the project “TKAine: System of Bioresorbable Implants for Sustained Postsurgical Analgesia Following TKA”. From public records Source · Oct 12, 2026

Keywords: pain Total Knee Arthroplasty (Postoperative Pain) Acute Postoperative Pain ATX-101 ATX101

Profile checked Oct 10, 2026

2Trials (company is sponsor)1NIH grants

Timeline

  1. Debt Debt financing — Series D: $57.5M (total, as published), announced Jun 5, 2025. Source: company's own press page. source ↗
  2. Trial start Phase 2: Study Assessing Pain Relief After Replacement of the Knee source ↗
  3. Trial start Phase 2: Study Assessing Pain Relief After Replacement of the Knee source ↗

Funding

Debt: $57.5M. Last 2 years.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT06799845Study Assessing Pain Relief After Replacement of the KneePhase 2CompletedFeb 3, 2025Oct 3, 2025 (actual)
NCT05260008Study Assessing Pain Relief After Replacement of the KneePhase 2TerminatedJun 7, 2022Jan 15, 2024 (actual)

NIH awards 1

Annual award amounts. Total $251K.

Feedback